---
document_datetime: 2024-08-08 17:12:28
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nexviadyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nexviadyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0328725
conversion_datetime: 2025-12-21 23:01:30.170362
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nexviadyme

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0018               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                         | 06/08/2024                          |                                             | PL                               |           |
| IA/0017              | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or | 28/05/2024                          | n/a                                         |                                  |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                         |            |            |             |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| II/0015             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                           | 04/04/2024 |            | SmPC and PL |                                   |
| PSUSA/11002 /202308 | Periodic Safety Update EU Single assessment - avalglucosidase alfa                                                                                                                                          | 07/03/2024 | n/a        |             | PRAC Recommendation - maintenance |
| II/0008             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                           | 30/11/2023 | 21/03/2024 | SmPC and PL |                                   |
| II/0012             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                               | 16/11/2023 | n/a        |             |                                   |
| IB/0011             | B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line) | 31/08/2023 | n/a        |             |                                   |
| PSUSA/11002 /202302 | Periodic Safety Update EU Single assessment - avalglucosidase alfa                                                                                                                                          | 31/08/2023 | n/a        |             | PRAC Recommendation - maintenance |
| IA/0013             | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                 | 01/08/2023 | n/a        |             |                                   |
| IA/0010/G           | This was an application for a group of variations.                                                                                                                                                          | 24/05/2023 | 21/03/2024 | Annex II    |                                   |

<div style=\"page-break-after: always\"></div>

|                     | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient           |            |            |                        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IAIN/0007           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                              | 05/04/2023 | 21/03/2024 | SmPC, Labelling and PL |                                   |
| PSUSA/11002 /202208 | Periodic Safety Update EU Single assessment - avalglucosidase alfa                                                                                                                                                                                                                                                                                                                                                                                      | 16/03/2023 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0006             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                            | 21/12/2022 | n/a        |                        |                                   |
| IB/0005/G           | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement | 22/11/2022 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0003/G | This was an application for a group of variations. B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP | 06/10/2022 | n/a |
| II/0002   | B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 22/09/2022 | n/a |
| II/0001   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/09/2022 | n/a |